Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Rallybio Corporation (RLYB:NASDAQ), powered by AI.
Rallybio Corporation is currently trading at $14.12. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Rallybio Corporation on Alpha Lenz.
Rallybio Corporation's P/E ratio is -1.3.
“Rallybio Corporation trades at a P/E of -1.3 (undervalued) with modest ROE of -68.8%.”
Ask for details →Rallybio Corporation is a biopharmaceutical company focusing on the development and commercialization of transformative therapies for severe and rare diseases. The company's primary purpose is to harness scientific advancements to address unmet medical needs, targeting life-threatening conditions that often lack effective treatment options. Rallybio invests in research and partnerships to explore innovative therapeutic approaches, with an emphasis on speed and efficiency in drug development. The sectors most impacted by Rallybio's work include biotechnology and healthcare, particularly concerning genetic disorders and immunological diseases. As a player within the biopharmaceutical space, the company contributes to the broader healthcare industry's efforts to improve patient outcomes and advance medical science. Rallybio's strategic collaborations with global research institutions and its commitment to scientific excellence underscore its significant role in delivering medical breakthroughs to the market. Launched with a mission to make a difference in patients’ lives, Rallybio embodies the forward momentum of biopharmaceutical innovation.
“Rallybio Corporation trades at a P/E of -1.3 (undervalued) with modest ROE of -68.8%.”
Ask for details →Rallybio Corporation (ticker: RLYB) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 20 employees. Market cap is $77M.
The current price is $14.12 with a P/E ratio of -1.33x and P/B of 1.25x.
ROE is -68.85% and operating margin is -9511.95%. Annual revenue is $636,000.